V. Molecular classification and risk stratification of myeloma

od Bergsagel, P. Leif, Chesi, Marta
Wydane 2013

Many Multiple Myelomas: Making More of the Molecular Mayhem

od Chesi, Marta, Bergsagel, P. Leif
Wydane 2011

Molecular pathogenesis of multiple myeloma: basic and clinical updates

od Chesi, Marta, Bergsagel, P. Leif
Wydane 2013

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression

od Hussain, Sajjad, Bedekovics, Tibor, Chesi, Marta, Bergsagel, P. Leif, Galardy, Paul J.
Wydane w Oncotarget (2015)

Promiscuous translocations into immunoglobulin heavy chain switch regions in multiple myeloma

od Bergsagel, P. Leif, Chesi, Marta, Nardini, Elena, Brents, Leslie A., Kirby, Suzanne L., Kuehl, W. Michael
Wydane 1996

Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination

od Akhmetzyanova, Ilseyar, McCarron, Mark J., Parekh, Samir, Chesi, Marta, Bergsagel, P. Leif, Fooksman, David R.
Wydane w Leukemia (2019)

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

od Chesi, Marta, Nardini, Elena, Brents, Leslie A., Schröck, Evelin, Ried, Thomas, Kuehl, W. Michael, Bergsagel, P. Leif
Wydane 1997

Erythroblast apoptosis and microenvironmental iron restriction trigger anemia in the VK*MYC model of multiple myeloma

od Bordini, Jessica, Bertilaccio, Maria Teresa Sabrina, Ponzoni, Maurilio, Fermo, Isabella, Chesi, Marta, Bergsagel, P. Leif, Camaschella, Clara, Campanella, Alessandro
Wydane w Haematologica (2015)

MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites

od Pei, Huadong, Zhang, Lindsey, Luo, Kuntian, Qin, Yuxin, Chesi, Marta, Fei, Frances, Bergsagel, P. Leif, Wang, Liewei, You, Zhongsheng, Lou, Zhenkun
Wydane 2011

Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy

od Chesi, Marta, Matthews, Geoffrey M., Garbitt, Victoria M., Palmer, Stephen E., Shortt, Jake, Lefebure, Marcus, Stewart, A. Keith, Johnstone, Ricky W., Bergsagel, P. Leif
Wydane 2012

Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells

od Tanno, Toshihiko, Lim, Yiting, Wang, Qiuju, Chesi, Marta, Bergsagel, P. Leif, Matthews, Geoff, Johnstone, Ricky W., Ghosh, Nilanjan, Borrello, Ivan, Huff, Carol Ann, Matsui, William
Wydane 2014

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma

od Affer, Maurizio, Chesi, Marta, Chen, Wei-Dong G., Keats, Jonathan J., Demchenko, Yulia N., Roschke, Anna V., Van Wier, Scott, Fonseca, Rafael, Bergsagel, P. Leif, Kuehl, W. Michael
Wydane 2014

CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma

od Murray, Megan E., Gavile, Catherine M., Nair, Jayakumar R., Koorella, Chandana, Carlson, Louise M., Buac, Daniela, Utley, Adam, Chesi, Marta, Bergsagel, P. Leif, Boise, Lawrence H., Lee, Kelvin P.
Wydane 2014

Modifications of the mouse bone marrow microenvironment favor angiogenesis and correlate with disease progression from asymptomatic to symptomatic multiple myeloma

od Calcinotto, Arianna, Ponzoni, Maurilio, Ria, Roberto, Grioni, Matteo, Cattaneo, Elena, Villa, Isabella, Sabrina Bertilaccio, Maria Teresa, Chesi, Marta, Rubinacci, Alessandro, Tonon, Giovanni, Bergsagel, P Leif, Vacca, Angelo, Bellone, Matteo
Wydane w Oncoimmunology (2015)

Multiple myeloma cells’ capacity to decompose H(2)O(2) determines lenalidomide sensitivity

od Sebastian, Sinto, Zhu, Yuan X., Braggio, Esteban, Shi, Chang-Xin, Panchabhai, Sonali C., Van Wier, Scott A., Ahmann, Greg J., Chesi, Marta, Bergsagel, P. Leif, Stewart, A. Keith, Fonseca, Rafael
Wydane w Blood (2017)

Overexpression of transcripts originating from the MMSET locus characterizes all t(4;14)(p16;q32)-positive multiple myeloma patients

od Keats, Jonathan J., Maxwell, Christopher A., Taylor, Brian J., Hendzel, Michael J., Chesi, Marta, Bergsagel, P. Leif, Larratt, Loree M., Mant, Michael J., Reiman, Tony, Belch, Andrew R., Pilarski, Linda M.
Wydane 2005

Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity

od Tiedemann, Rodger E., Mao, Xinliang, Shi, Chang-Xin, Zhu, Yuan Xiao, Palmer, Stephen E., Sebag, Michael, Marler, Ron, Chesi, Marta, Fonseca, Rafael, Bergsagel, P. Leif, Schimmer, Aaron D., Stewart, A. Keith
Wydane 2008

Tumoricidal Effects of Macrophage-activating Immunotherapy in a Murine Model of Relapsed/ Refractory Multiple Myeloma

od Jensen, Jeffrey L., Rakhmilevich, Alexander, Heninger, Erika, Broman, Aimee Teo, Hope, Chelsea, Phan, Funita, Miyamoto, Shigeki, Maroulakou, Ioanna, Callander, Natalie, Hematti, Peiman, Chesi, Marta, Bergsagel, P. Leif, Sondel, Paul, Asimakopoulos, Fotis
Wydane w Cancer Immunol Res (2015)

AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies

od Chesi, Marta, Robbiani, Davide F., Sebag, Michael, Chng, Wee Joo, Affer, Maurizio, Tiedemann, Rodger, Valdez, Riccardo, Palmer, Stephen E., Haas, Stephanie S., Stewart, A. Keith, Fonseca, Rafael, Kremer, Richard, Cattoretti, Giorgio, Bergsagel, P. Leif
Wydane 2008

TPL2 kinase regulates the inflammatory milieu of the myeloma niche

od Hope, Chelsea, Ollar, Samuel J., Heninger, Erika, Hebron, Ellen, Jensen, Jeffrey L., Kim, Jaehyup, Maroulakou, Ioanna, Miyamoto, Shigeki, Leith, Catherine, Yang, David T., Callander, Natalie, Hematti, Peiman, Chesi, Marta, Bergsagel, P. Leif, Asimakopoulos, Fotis
Wydane 2014